108 results about "Cirrhotic patient" patented technology

A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. a human) to physiological processes within the host. Information regarding the types and relative amounts of gut microflora is correlated with physiological processes indicative of e.g., a patient's risk of developing a disease or condition, likelihood of responding to a particular treatment, for adjusting treatment protocols, etc. The information is also used to identify novel suitable therapeutic targets and/or to develop and monitor the outcome of therapeutic treatments. An exemplary disease/condition is the development of hepatic encephalopathy (HE), particularly in patients with liver cirrhosis.

The invention discloses a kit for detecting liver fibration or liver cirrhosis caused by hepatitis B virus infection. Whether an individual has liver fibration or liver cirrhosis conditions or not is determined through detecting the level of CHI3L1 in an individual sample. The kit includes: (1) an antibody bound to the CHI3L1; (2) a labeled antibody bound to the CHI3L1 when the CHI3L1 is bound to the antibody limited in (1); and (3) a standard sample composed of a solution containing a known amount of the CHI3L1, wherein the CHI3L1 is from serum of a liver fibration or liver cirrhosis patient caused by the hepatitis B virus infection.

By means of a proteomic approach, the markers of hepatocellular carcinoma (HCC) in the liver of a knockout mouse (MAT1A−/−) have been identified for the MAT1A gene (deficient in the synthesis of S-adenosylmethionine). 27 proteins have been detected the expression thereof is altered in, at least, 50% of the analysed tumours. Amongst them, 13 proteins have been validated in biopsies of patients with HCC of different etiology, and 7 of them have been validated in biopsies of patients with liver cirrhosis, a stage prior to the development of HCC, which makes it possible to differentiate between prior stages of the disease and even between different etiologies (viral and alcoholic). Having a panel of markers available may contribute to more accurately defining the alterations associated with the development of HCC and thus facilitate prognosis and diagnosis of this disease.

The invention discloses a liver cell liver cancer diagnosis combination composed of serum microRNA (microribonucleic acid) and a kit the combination. The liver cancer diagnosis combination comprises microRNAs:hsa-miR-29a, hsa-miR-29c, hsa-miR-133a, hsa-miR-143, has-miR-145, hsa-miR-192 and hsa-miR-505. The diagnosis combination and kit can be used for distinguishing a liver cancer patient from a healthy person, hepatitis virus carrier, chronic hepatitis patient or hepatocirrhosis patient.

In one embodiment, the present invention is directed to methods for diagnosis of acute kidney injury (AKI) and hepatorenal syndrome (HRS) in cirrhosis patients, and to methods for distinguishing between AKI and/or HRS and/or other kidney diseases in cirrhosis subjects. In another embodiment, the present invention is directed to prognostic methods for predicting disease-specific mortality in cirrhosis patients. In some aspects, the diagnostic and prognostic methods of the invention are based on determining whether a bodily fluid sample, such as a urine sample, contains an amount of NGAL protein that exceeds or is less than a certain threshold level, or that falls within a certain range.

The present invention provides, as a pharmaceutical agent having an effect to inhibit the development and/or progression of liver cancer in hepatitis C virus-positive human cirrhosis patients, an agent for inhibiting the development and/or progression of liver cancer in hepatitis C virus-positive human cirrhosis patients, which contains three kinds of amino acids of isoleucine, leucine and valine.

The invention provides microRNA molecular marker combination of liver cirrhosis. The combination comprises more than one microRNA molecules of nucleic acid with sequence numbers of 1-24 and 54. The invention further provides use of preparing a liver cirrhosis diagnostic reagent. Compared with the content of the microRNA molecular marker of a hepatitis B patient in plasma/serum, the content of the microRNA molecular marker of a liver cirrhosis patient in plasma/serum is remarkably different, so that the liver cirrhosis patient and the hepatitis B patient can be effectively differentiated. When the expression level of the microRNA molecular marker reaches the level of liver cirrhosis, liver cirrhosis can be diagnosed. The invention further provides a diagnostic reagent kit for liver cirrhosis. The microRNA molecular marker of liver cirrhosis provided by the invention is used for guiding diagnosis of liver cirrhosis and has the characteristics of being simple in operation, safe, free from damage, high in specificity, high in sensitivity and easy to screen massively.

The invention discloses a biomarker of liver cirrhosis, and an application thereof. Association analysis of the whole intestinal flora microorganisms is developed from stool samples of 98 patients suffering from liver cirrhosis and 83 healthy references to study and describe stool microflora and functional component characteristics. 15 genes form the biomarker as a highly accurate index for distinguishing the patients. The discovery is examined in other independent population to confirm the accuracy of the biomarker; and associated robustness between the detection flora and the liver cirrhosis are confirmed. The biomarker is at least 10 genes selected from the following group of 15 genes. 15 genes are enriched in the intestinal flora of the patients suffering from the liver cirrhosis. The invention also relates to a drug for treating the liver cirrhosis. The drug can promote or increase the number or expression of the genes. The invention also relates to a method for producing or screening the drug. The drug can promote or increase the number or expression of the biomarker. The invention also relates to a kit for detecting the liver cirrhosis, monitoring a treatment process, or producing and screening the drug. The kit is used for detecting the biomarker.

The invention relates to a construction method for a differential expression profile model of hepatitis B virus (HBV) infectivity and alcoholic cirrhosis. According to the method, peripheral blood samples of liver cirrhosis patients with HBV infections, alcoholic cirrhosis patients and healthy people are sampled to carry out nulcear magnetic resonance analysis, then a multi-variable statistical analysis is adopted for the resulting spectrograms from the nulcear magnetic resonance analysis to obtain the differential expression profile model of the HBV infectivity and the alcoholic cirrhosis. According to the present invention, the metabonomics analysis method is adopted for analyzing the metabolic products of the liver cirrhosis patients with HBV infections, the alcoholic cirrhosis patients and the healthy people, such that the specific metabolic products related to the pathologic mechanisms of the liver cirrhosis with the HBV infection and the alcoholic cirrhosis are found, the differential expression profile model of the HBV infectivity and the alcoholic cirrhosis is constructed; such that a support is provided for specific diagnosis and treatment of the liver cirrhosis with the HBV infection and the alcoholic cirrhosis. In addition, the invention further relates to a differential expression profile model of the HBV infectivity and the alcoholic cirrhosis.

The invention discloses a construction method of a decompensated liver cirrhosis combined infection risk prediction model. The method comprises the following steps: S1, data acquisition: collecting decompensated liver cirrhosis patient information; S2, data preprocessing: cleaning and sorting the original data; S3, index screening by adopting LASSO regression: dividing the patients into an infection group and a non-infection group according to whether the patients have combined infection or not, and performing single-factor analysis on the grouped index data of the patients to obtain single-factor meaningful indexes; bringing the single-factor meaningful indexes into Lasso regression for index re-screening to obtain indexes for constructing a prediction model; and S4, prediction model construction: constructing the prediction model by using the indexes screened by Lasso regression through multi-factor Logistic regression. The method is based on application of a clinical big data methodand is high in reliability; the constructed model is simple and easy to use, and the used indexes can be obtained through conventional inspection and are easy to obtain.

The invention discloses a microbial marker of liver cirrhosis, and an application. The microbial marker is one or more selected from one microorganism of Veillonella atypica ACS-134-V-Col7a enriched in a patient group suffering the liver cirrhosis or two microorganisms of Bacteroides uniformis ATCC8492 and Clostridiales enriched in a healthy group. The invention also relates to a drug for treating the liver cirrhosis. A drug for treating the liver cirrhosis can promote or increase one or two selected from the two microorganisms of Bacteroides uniformis ATCC8492 and Clostridiales enriched in the healthy group, and/or suppress or clear the microorganism of Veillonella atypica ACS-134-V-Col7a enriched in the patient group suffering the liver cirrhosis. The method detects relative abundance of the microbial marker in intestinal flora and compares the obtained relative abundance value and a predetermined cutoff value. The invention also relates to a beneficial microorganism combination or functional food. The beneficial microorganism combination or functional food comprises one or two of the two microorganisms of Bacteroides uniformis ATCC8492 and Clostridiales enriched in the healthy group. The invention also relates to a kit for detecting the liver cirrhosis, monitoring a treatment process, or producing and screening the drug. The kit is used for detecting the microbial marker.

The invention relates to a marker for intestinal microecology and application thereof, in particular to a biomarker used for early diagnoses of liver cancer. The biomarker used for early diagnoses ofliver cancer is composed of 34 kinds of genes shown as SEQ ID NO:1-34, and the genes are enriched in intestinal tracts. The invention also provides a detection reagent, and the reagent includes a primer used for detecting the 34 kinds of genes shown as SEQ ID NO:1-34. Feces of patients in groups are collected through a noninvasive method, and 16S rRNA Miseq sequencing of intestinal florae is conducted. During a discovery period of the biomarker, through a random forest law, microorganism gene markers with specificity of early liver cancer are identified among patients suffering from early cirrhosis and liver cancer, patients suffering from cirrhosis and healthy comparisons, an index of a probability of disease (POD) of liver cancer is created, and verification of the markers during the discovery period is achieved. During the verification period of the markers, the POD index of the patients during the verification period is calculated, and verification of the diagnosis value of the patients suffering from liver cancer during the verification period according to the POD index is achieved.

The invention belongs to the technical field of proteins, and relates to the detection of glycoprotein, specifically to a detection method of the IgG core fucosylation level and a use thereof, wherein the method comprises the step of calculating the IgG amount of the core fucosylation/the glycoprotein total amount of the core fucosylation. The method can not distinguish healthy persons from hepatitis B patients, but can distinguish whether the diagnosed hepatitis B patient is a chronic hepatitis patient or a cirrhosis patient.

The invention relates to a hepatitis B compensated stage liver cirrhosis screening model building method based on a random forest algorithm. The method comprises the steps of collecting data; preprocessing data; building a hepatitis B compensated stage liver cirrhosis screening classification model based on the random forest algorithm; testing and evaluating the classification model. According to the technical scheme, serum indexes, type-B ultrasonic imaging features and other sample data, collected in recent three years, of hepatitis B patients and compensated stage liver cirrhosis patients are used for building a noninvasive hepatitis B compensated stage liver cirrhosis forewarning model. On the basis of the model, whether a hepatitis B patient (to-be-tested sample) is in the period of compensated stage liver cirrhosis or not can be effectively predicted, and the disease progression and prognosis conditions of the hepatitis B patient can be evaluated. On the basis of evaluation of the model, unnecessary liver tissue biopsy pathological examinations can be reduced.

The invention relates to a marker or a composite thereof for liver cancer detection, a reagent and a detection kit for detecting liver cancer, and application of the marker or the composite thereof, the reagent and the detection kit in detecting liver cancer and distinguishing patients with liver cancer, patients with liver cirrhosis and/or healthy people.

The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta/delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-III, apolipoprotein E, C4b-binding protein beta chain, intact/cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase/arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein. These biomarkers can be used in conjunction with polypeptides in WO/2008/031051. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.

The invention provides a test kit for detecting the content of 5-hydroxymethyl cytosine and application thereof. The content of a gene marker 5-hydroxymethyl cytosine is detected through the test kit,and the canceration condition of a patient with liver cirrhosis is judged by using the detection result of the content of 5-hydroxymethyl cytosine in the gene marker. The test kit provided by the invention has high accuracy and can quickly react when being applied to liver cancer detection, and has high sensitivity and specificity for liver cirrhosis detection and dynamic monitoring of liver cirrhosis to liver cancer; the operability is high, and detection can be carried out only by collecting venous peripheral blood; compared with a conventional tissue biopsy technology, the detection methodusing the test kit is non-invasive, and can be frequently carried out for many times; the test kit disclosed by the invention is relatively low in detection cost and relatively high in acceptabilityof subjects.

The invention discloses a cirrhosis microRNA molecular marker composition, with sequence No. ranging from 1 to 13, as well as application of the molecular marker composition in preparing a cirrhosis personalized medicine diagnostic reagent. Due to a significant difference between content of a microRNA molecular marker of a cirrhosis patient in plasma/serum and content in plasma/serum in health control, cirrhosis patient can be effectively distinguished from people of the health control; in a process of applying medicines to the cirrhosis patient, administration can be stopped by guiding and assistance, when cirrhosis outcome microRNA molecular marker is adjusted to a normal level. Furthermore, the invention discloses a diagnostic kit for guiding personalized administration of the cirrhosis. The liver cirrhosis outcome microRNA molecular marker disclosed by the invention, when being used for guiding personalized administration of cirrhosis patients, has characteristics of being simple to operate, safe and noninvasive, high in specificity, high in sensitivity and easy in massive screening.

The present invention relates to a kit for diagnosing hepatocellular carcinoma consisting of plasma microRNA, a kit containing the same, and a new method therefor. The marker for diagnosing hepatocellular carcinoma consists of a plurality of nucleic acid molecules, each nucleic acid molecule encoding at least one microRNA sequence, preferably consists of nucleic acid molecules encoding hsa-miR-122, hsa-miR-192, hsa-miR-21, hsa-miR-223, hsa-miR-26a, hsa-miR-27a, hsa-miR-801 and hsa-miR-1228. The kit can be used for diagnosing hepatocellular carcinoma, especially early hepatocellular carcinoma, and also for discriminating plasma of at least one hepatocellular carcinoma patient from that of at east one healthy individual, at east one chronic hepatitis B patient, or at east one cirrhosis patient.

The invention provides a hepatitis b /hepatic cirrhosis microRNA molecular marker combination, which comprises more than one micro RNA nucleic acid molecules selected from mir.146a-5p, miR-22-3P and miR-381.3P, and a purpose of the marker combination for preparing hepatitis b/hepatic cirrhosis infection diagnosis and/or prognosis assessment kit. Due to a significant difference between content of a microRNA molecular marker of a hepatitis b/hepatic cirrhosis patient in plasma/serum and content in plasma/serum in health control, the hepatitis b/hepatic cirrhosis patient can be effectively distinguished from people of the health control; a chronic hepatitis b/hepatic cirrhosis disease state can be comprehensively analyzed, which can be used for guiding the patient treatment and usage of medication. The invention also provides a diagnostic kit for guiding the hepatitis b/hepatic cirrhosis infection diagnosis and/or prognosis assessment. By using the hepatitis b/hepatic cirrhosis microRNA molecular marker and the diagnostic kit, infection diagnosis and/or prognosis assessment of the hepatitis b/hepatic cirrhosis patient can be guided, and the combination has the characteristics of simple operation, safety and no wound, high specificity, high sensitivity and easy massive screening.

The invention provides a diuresis inducing plaster for relieving ascites due to cirrhosis. The plaster is prepared by the following steps: selecting and drying the following raw materials by weight: euphorbia kansui, semen pharbitidis, astragalus membranaceus, bighead atractylodes rhizome, cortex cinnamomi and pericarpium citri reticulatae viride, grinding the raw materials and filtering by virtue of a sieve of 200 meshes; blending the ground materials with honey and a transdermal penetration enhancer to obtain a paste, and uniformly stirring; spreading 80-100 of the paste on patch according to the ascites area of a patient; and sticking and applying to Shenque acupuncture point, Guanyuan acupuncture point, Shuifen acupuncture point, Shuidao acupuncture point and Zhongwan acupuncture point, wherein the diuresis inducing plaster is mainly used for treating intractable ascites caused by decompensated liver cirrhosis. The diuresis inducing plaster has functions of warming kidney and invigorating spleen, regulating qi circulation and inducing diuresis; the diuresis inducing plaster is capable of overcoming the shortcoming of an oral medicine which is always poor in effect on cirrhosis patients who have poor metabolism and detoxification capacities, and the plaster has the advantages of being low in toxic and side effects and capable of attacking pathogen without causing hurt to healthy qi; the plaster can make up the deficiency of internal therapy by Western medicine and traditional Chinese medicine; the plaster is convenient and easy in administration, easily acceptable to patients, significant in diuresis effect and durable in curative effect; and upon clinical observation, total effective rate of treatment is 93.3%.

The invention discloses an ultra-early liver cancer related screening and evaluating product based on a saliva specific glycoprotein sugar chain structure and application. Aiming at a saliva sample, aproduct for screening, early diagnosis, risk assessment, drug screening and/or curative effect assessment of the ultra-early liver cancer is provided, whether the saliva sample contains any one or any combination of specific 26 N-sugar chains or not is detected, and whether a saliva sample main body is an ultra-early liver cancer patient (not a liver cirrhosis patient) or not can be judged. Correspondingly, lectin playing a role in specific binding recognition is MAL-I and can be independently used as a reagent for recognizing a saliva specific glycoprotein sugar chain structure to be used for preparing related medical products.

The present invention provides a method and a kit for accurately predicting the prognosis (mortality rate) and risk of developing hepatocellular carcinoma in liver cirrhosis patients. The present invention provides: a method by which an 'index for evaluating the risk of developing hepatocellular carcinoma, 'which is used for predicting the prognosis and risk of developing hepatocellular carcinomain liver cirrhosis patients, is calculated as the ratio of CSF1R that contains WFA/VVA-binding sugars relative to the total CSF1R content of bodily fluid (blood serum) (WFA+-CSF1R%); and a method by which a 'prognosis evaluation index ' is calculated as the amount of CSF1R that contains WFA/VVA-binding sugars (WFA+-CSF1R ng/mL). Furthermore, an optimal cutoff value was determined for each of the indices, and it was proven that: the risk of developing hepatocellular carcinoma was significantly high when the 'index for evaluating the risk of developing hepatocellular carcinoma ' in a subject wasequal to or greater than the optimal cutoff value; and the prognosis was significantly poor when the 'prognosis evaluation index ' was equal to or greater than the optimal cutoff value. In addition,anti-CSF1R antibodies (CSR-1-30), which are exceptional for detecting CSF1Rs such as CSF1Rs that contain WFA/VVA-binding sugars in a bodily fluid sample, were provided. It was discovered that srWFA and VVA lectins other than WFA lectins can be used, and it was additionally proven that measuring the amount of CSF1R that binds to a CSF1R-specific lectin is preferable to measuring the total amount ofCSF1R. It was also possible to provide, inter alia, a kit for measuring the 'prognosis evaluation index ' and/or 'index for evaluating the risk of developing hepatocellular carcinoma ' in a liver cirrhosis patient, the kit including these anti-CSF1R antibodies and lectins as constituent elements.

The invention discloses a spleen-invigorating and diuresis-promoting preparation for patients with earlier period cirrhosis and a preparation method for the preparation. The spleen-invigorating and diuresis-promoting preparation is prepared from the following main raw materials in parts by weight: 10-15 parts of curcuma aromatica, 8-16 parts of rhizoma anemarrhenae, 12-18 parts of poria cocos, 5-10 parts of cortex acanthopanacis, 7-15 parts of kummerowia striata, 16-20 parts of angelica sinensis, 11-17 parts of dahurian patrinia herb, 6-13 parts of rosa davurica pall, 11-16 parts of dried radix rehmanniae, 15-20 parts of codonopsis pilosula, 9-13 parts of fingered citron, 4-9 parts of fried malts and 8-15 parts of sargentodoxa cuneata. The preparation can be used for treating both symptoms and root causes; low possibility of relapse is achieved, and the treating cost is low; the economic burden of the patient can be relieved; no side effect, and no adverse effect are achieved; the paint of the patient can be obviously relieved.